Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
26 juil. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical
12 juil. 2022 06h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 12, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
17 mai 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and...
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
10 mai 2022 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE® Significant Cash Position of $198 Million and...
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
25 avr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
16 mars 2022 16h21 HE
|
Catalyst Pharmaceuticals, Inc.
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE...
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
11 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
08 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
03 mars 2022 09h20 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
02 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio ...